Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019. The bill, if passed, would allow Medicare to negotiate drug prices using 120% of international reference price as the payment upper limit.
Together with Mark Trusheim of MIT Sloan School of Management and Preston Atteberry, MD, the Drug Pricing Lab team articulated why biosimilars are not and will not effectively lower the price of biologic drugs after the period of market exclusivity.
Preston J. Atteberry, Peter B. Bach, Jennifer A. Ohn, Mark R. Trusheim
Anna Kaltenboeck and Dr. Peter Bach published commentary in Morning Consult, describing key misconceptions surrounding outcomes-based contracting, and what steps are needed to make the approach value-based.